ArticleMetabolic brain disease2024
Assessment of blood-brain barrier injury in hypertensive CSVD by 11.7TMR T1mapping and microvascular pathologic changes.
Article in Metabolic brain disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We used spontaneously hypertensive rats (SHR) as a hypertensive cerebral small vessel disease (CSVD) model to quantify blood-brain barrier (BBB) disruption by 11.7TMR T1mapping and to investigate white matter lesions and microangiopathy in CSVD. Male SHR were used as a hypertensive CSVD animal model and normotensive Wistar-Kyoto rats (WKY) were used as a control model. After 18 weeks, the rats did the Morris water maze test were evaluated, blood-brain barrier (BBB) integrity were evaluated by using Bruker 11.7T MR T1 mapping. ITK-SNAP software was used to measure hippocampal volume. Then, pathological analysis was carried out on rats, myelin integrity, vascular permeability and microvessel density were assessed by immunohistochemistry. Our data showed that hypertensive CSVD model exhibited decreased memory function, BBB leakage could be detected differently in different brain regions, and T1 values of the hippocampus showed the greatest drop than other areas. Furthermore, the pathological changes in small vessels were more extensive, average optical density of myelin basic protein (MBP) in the white matter of SHR group was significantly reduced, moreover, VEGFR2 immunoreactivity scores (IRS) and CD34-assessed MVD in SHR group were significantly higher than WKY group. We find different parts of the brain tissues have different degrees of BBB leakage, hippocampal atrophy and hippocampal volume were decreased in hypertensive CSVD by using T1 Mapping. Loss of myelin integrity, vascular permeability increased and microangiopathy may contribute to hypertensive-related BBB functional deficits in CSVD model.
Indexed as
Identifiers
39680228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.